Peripherally Inserted Central Catheter (PICC): Building a Safe, Precise, and Efficient "Lifeline" — 2026 Global PICC Product and Technology Frontiers

Introduction

In clinical settings such as oncology chemotherapy, long-term parenteral nutrition, intensive care, and prolonged antibiotic therapy, establishing a safe and reliable central venous access is often directly linked to patient outcomes and quality of life. The Peripherally Inserted Central Catheter (PICC), owing to its minimally invasive nature, safety profile, and bedside operability, is increasingly becoming the first-line choice for intravenous therapy.

The global PICC market is growing steadily. According to market research reports, the global PICC market size was approximately USD 868 million in 2024 and is projected to exceed USD 1 billion by 2030. Other sources estimated the market at between USD 1.07 billion and USD 1.25 billion in 2025, with expectations to reach USD 1.8–3.2 billion by 2032. This sustained expansion underscores the pressing clinical demand for high-quality Vascular Access solutions.

I. Product Overview: Diverse PICC Solutions for Varied Clinical Needs

Current PICC product portfolios have evolved into a rich matrix, offering refined choices based on lumen count, pressure tolerance, and patient population:

· By Lumen Configuration:

Single-lumen, double-lumen, and multi-lumen PICCs, catering to single-infusion therapies and multi-channel combination treatments.

· By Functionality:

Standard PICC: Suitable for general intravenous infusion.

Power-Injectable PICC (Power PICC): Capable of withstanding high-pressure injections, making it compatible with contrast-enhanced CT scans and central venous pressure monitoring—facilitating integrated diagnosis and therapy.

· By Patient Population:

Adult PICC: Widely used in oncology, critical care, and long-term infusion patients.

Neonatal PICC: Ultra-thin catheters designed for premature and low-birth-weight infants. In 2026, the world’s thinnest PICC (outer diameter 0.33 mm, approximately 1.0 Fr) was successfully applied clinically, providing a dedicated "lifeline" for extremely low-birth-weight neonates.

In terms of materials and manufacturing, next-generation PICC products continue to break new ground. For example, Endexo® technology incorporates a permanent, non-eluting polymer into the polyurethane catheter material; data show an 87% reduction in thrombus accumulation compared to standard PICCs. In 2026, Access Vascular partnered with Medline to launch HydroPICC®, the first PICC to receive an FDA anti-thrombotic indication, reducing thrombotic and infectious risks from the material level.

II. Technological Innovation: From "Blind" Placement to Image-Guided Precision—The Era of Smart Insertion

Traditional PICC placement relies heavily on operator experience and requires post-procedural chest X‑ray to confirm tip location, carrying risks of malposition, radiation exposure, and prolonged procedure times. In recent years, intelligent positioning systems such as the 3CG magnetic navigation technology have fundamentally transformed this process.

3CG Magnetic Navigation Technology integrates three core modalities—electromagnetic tracking, ultrasound guidance, and intracavitary electrocardiography (ECG)—into a "trinity" navigation system. During placement, the tracking device on the catheter tip provides a real-time "map" of the catheter's intravascular trajectory on the screen, enabling precise, dynamic localization. This technology offers three major advantages: real-time tracking, intelligent tip confirmation, and a radiation-free, safe procedure. Numerous healthcare institutions in China, including Maoming People's Hospital, Peking University Shougang Hospital, and Guangzhou Panyu Central Hospital, have successfully adopted 3CG‑guided PICC placement.

Meanwhile, Piccolo Medical's second-generation SmartPICC® technology received FDA 510(k) clearance in July 2025. This system enables real-time, precise bedside tip confirmation using the patient's cardiac electrical activity, eliminating the need for post-placement chest X‑ray—significantly streamlining workflow and reducing patient wait times. Its proprietary ion dilution navigation technology provides real-time guidance during insertion and immediately detects aberrant catheter advancement.

Additionally, a prospective clinical study initiated in 2026 is utilizing the Sherlock 3CG system to assess the impact of PICC placement on venous wall integrity. By comparing pre- and post-placement ultrasound images, this study aims to quantify the long-term effects of the catheter on vessel walls. These technological innovations collectively propel PICC placement from an experience‑driven procedure toward a data‑driven era of precision medicine.

III. Clinical Value: Core Advantages of PICC and Latest Evidence

The broad clinical acceptance of PICC stems from its multidimensional benefits:

1. Minimally Invasive and Safe: Inserted via peripheral veins (typically the basilic, brachial, or cephalic veins of the upper arm), avoiding serious complications such as pneumothorax or arterial injury associated with subclavian or internal jugular puncture.

2. Bedside Procedure: Can be performed by trained nurses at the bedside, eliminating the need for operating room resources and reducing procedural delays.

3. Long‑Term Use: Suitable for patients requiring extended venous access, e.g., chemotherapy, total parenteral nutrition, and prolonged antibiotic therapy.

4. Infection Control: Antimicrobial‑coated PICCs (e.g., with chlorhexidine, silver ions) reduce bacterial colonization and extend dwell time.

III. Clinical Value: Core Advantages of PICC and Latest Evidence

Regarding complication management, a 2026 in vitro model study published in the Journal of Infusion Nursing compared two recanalization techniques for thrombotic PICC occlusion. Results showed that the intermittent negative‑pressure guidewire technique achieved a success rate of 62.79%, significantly superior to the 4.44% of the dwell‑locking technique (P < 0.0001), and required less procedure time. This finding provides robust evidence for managing PICC occlusions.

In terms of guidelines and standards, the 2025 Expert Consensus on the Safety and Use of Power‑Injectable PICCs for Contrast‑Enhanced CT Examinations systematically outlines standards for safe applications. The National Association of Neonatal Nurses (NANN) Clinical Practice Guideline: Peripherally Inserted Central Catheters in Neonates (4th Edition) offers authoritative guidance on placement, maintenance, and complication management for neonatal PICCs.

IV. Market Outlook: Sustained Growth Driven by Innovation

With global population aging, rising cancer incidence, and increasing chronic disease management needs, the PICC market is poised for steady growth. Various institutions project 2026 market sizes between USD 1.12 billion and USD 1.43 billion. Key growth drivers include:

· Technological Iteration: Continued innovation in smart navigation, antithrombotic materials, and antimicrobial coatings.

· Integrated Diagnostics and Therapy: Power‑injectable PICCs seamlessly bridge intravenous therapy with contrast‑enhanced imaging.

· Out‑of‑Hospital Expansion: Increasing use of PICCs in home infusion therapy and chronic disease management reduces hospitalization rates.

· Specialized Teams: Establishment of dedicated vascular access teams in hospitals to standardize PICC placement, maintenance, and removal protocols.

Conclusion

From experience‑based placement to intelligent navigation, and from simple infusion to integrated diagnostics and therapy, continuous innovation in PICC products and technologies is building a safer, more precise, and more efficient "lifeline" for patients worldwide. Looking ahead, as materials science, smart sensing, and clinical practice converge, PICC will remain an indispensable cornerstone of intravenous therapy, safeguarding the treatment and recovery of countless patients.

Disclaimer: This article is for medical popularization, purposes only and does not constitute professional medical advice. Please always follow the diagnosis and treatment plans provided by your treating physician.